Gamida Cell ^Public

Gamida Cell is a biopharmaceutical company focused on developing advanced cell therapies for patients with blood cancers and hematologic diseases. Their main goal is to improve and extend the life-saving benefits of hematopoietic stem cell transplant through their product, NiCord, which is a cell therapy based on NAM-expanded cord blood. They also have an investigational product called omidubicel, which has the potential to be a life-saving alternative for patients in need of bone marrow transplant. Gamida Cell's expansion platform supports the properties of NAM and allogeneic cell sources, making them a leader in the field of cell therapy.